Trial Profile
A Phase III, Open Label, Randomized, Multicenter, Parallel Group Trial to Assess the Efficacy and Safety of the Fixed Dose Combination of Arterolane Maleate 37.5 mg and Piperaquine Phosphate (PQP) 187.5 mg Dispersible Tablets in Comparison with Chloroquine Phosphate in Pediatric Patients with Acute Uncomplicated Plasmodium Vivax Malaria.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Arterolane/piperaquine (Primary) ; Primaquine (Primary) ; Chloroquine
- Indications Vivax malaria
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 31 Oct 2013 New trial record